|
Andromeda
Founded in 2007, Andromeda Biotech focuses on the development of innovative treatment for autoimmune diabetes. The Company's lead product, DiaPep277, currently in Phase III clinical trials, is a novel therapeutic approach for treating type 1 diabetes (T1D). It is a unique peptide derived from the human protein, HSP60, which immunomodulates the immune system, prevents the destruction of pancreatic cells that secrete insulin, and preserves their natural function.
To date, there is no therapy that can prevent the destruction of insulin secreting beta cells. DiaPep277 is designed to treat type 1 diabetes patients with residual insulin secreting cells. Target populations include newly diagnosed adult patients, type 1 diabetic children, people with high risk to develop type 1 diabetes, and type 1 diabetes patients with slow progressing disease.
A Phase III clinical study is currently being conducted in 40 medical centers in Europe, Israel, and South Africa.
|
|
MediWound
MediWound is an Israeli bio-tech company which develops and commercializes Debrase® – a first line, enzymatic eschar (necrotic tissue) removal agent. Debrase® can swiftly and selectively remove the eschar from burn tissue. The company's goal is to introduce an efficient and selective alternative treatment to the Standard of Care surgical eschar removal. Deep second and third degree burns result in a thick layer of eschar which must be removed prior to further treatment towards wound healing. This process is usually accomplished only by traumatic surgery or lengthy mechanical procedures.
In most cases following a single topical application of 4 hours of Debrase® at the patient bedside, the necrotic tissue can be wiped away leaving a clean healing or graftable wound bed. Thus, the use of Debrase® can minimizes the extent of traumatic and bloody surgery. Debrase® can selectively remove the opaque eschar leaving the viable tissues intact. Therefore, it allows burn experts to visually assess the wound bed, based on basic skin anatomy principles and to prescribe a diagnosis based treatment strategy towards spontaneous healing or skin grafting.
In August 2007, MediWound completed an investment deal with Teva pharmaceuticals and several institutional investors. Teva acquired an option to market Debrase® in North America and/or the EU and has a license to market Debrase® in the rest of the world.
In 2009 Debrase® completed successfully Phase III clinical trial. Mediwound is currently preparing for the registration of Debrase® in Europe.
Debrase® has an orphan drug status in both the US and EU.
|
|
D-Pharm
D-Pharm Ltd. is a biopharmaceutical company focused on the discovery and development of state-of-the-art drugs for the treatment of the most devastating brain diseases and cancer.
D-Pharm has a platform technology pioneering lipid-like medicine. The technology has translated into a rich proprietary product pipeline. The Company has three late-stage clinical programs: a Phase III product, DP-b99, for treatment of acute stroke patients; DP-VPA in Phase II for epilepsy and Phase II for migraine; and a number of pre-clinical and R&D stage products targeting Alzheimer's disease, neurodegeneration and cancer.
D-Pharm’s strategy is to maximize products’ value through advanced clinical studies and then to seek a Pharma or Biotech partner for worldwide development, registration and marketing.
The Company’s headquarters and research labs are based in Rehovot, Israel. The company is an integrated drug development organization.
D-Pharm was established in 1993 as a technological incubator by Dr. Alex Kozak Ph.D., the Company's CEO and President.
D-pharm is publicly traded in the Tel-Aviv stock exchange (TASE: DPRM)
|
|
CureTech
CureTech focuses on the research, development and commercialization of novel, broad-spectrum, immune modulating products for the treatment and control of cancer. CureTech's lead product, CT-011, is a humanized monoclonal antibody that interacts with PD-1, a B7 receptor-family-associated protein, is being developed for the treatment and control of cancer.
CT-011 was shown to effectively attenuate tumor growth and eliminate tumor metastases in a variety of model systems. A number of, international, multi center, Phase II clinical studies are ongoing including a clinical study in patients with diffuse large B cell lymphoma and a trial in patients with metastatic colorectal cancer.
In 2006, the Company signed a strategic collaboration agreement with Teva Pharmaceutical Industries for the development of CT 011.
|
|
Gamida Cell
Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.
Gamida Cells flagship product, StemEx®, is currently being studied as a treatment for hematological malignancies or blood cancers including leukemia and lymphoma in an open, global, pivotal Phase II/III
|
|
BioCancell
BioCancell Therapeutics, Inc. is a biopharmaceuticals corporation specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of numerous types of cancer. The Company's proprietary technology constitutes a novel paradigm for the targeted destruction of cancer cells, with no effect on normal surrounding tissue and no observed severe adverse effects, allowing for long-term, safe treatment and prevention of cancer. BC-819, BioCancell's leading product, is a plasmid in which H19 regulatory sequences drive the expression of Diphtheria Toxin A gene. It is in the clinical trial stage for bladder, ovarian and pancreatic cancer, and has shown efficacy in pre-clinical studies and compassionate use for diseases such as liver cancer and renal TCC.
BioCancell was co-founded in 2004 by Professor Avraham Hochberg, Professor of Molecular Biology at the Hebrew University of Jerusalem, based on technology developed by him over the past 15 years.
|
|
Polyheal Ltd.
Polyheal Ltd. is pioneering a revolutionary wound management approach by filling the large unmet need in the wound care market with a general stimulator of granulation, a major step in the healing process of acute and chronic wounds. Established in 1996, Polyheal is committed to implementing its unique proprietary scientific microsphere-based technology to develop, manufacture & commercialize advanced wound healing products for chronic wounds, skin ulcers, burns, trauma and post-surgery wounds. Polyheal's wound healing approach has shown a high rate of complete healing or wound improvement for skin grafts in a wide range of chronic wounds which were incurable by conventional treatments.
Polyheal-1, recently received marketing approval in Europe (CE Mark) and the company is in discussions with the FDA to obtain US approval. |
|
Aposense
Aposense Ltd. is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents based on the identification and targeting of cells undergoing apoptosis (programmed cell death). Apoptosis is a controlled, active program of cell death, inherent in every cell in the body, and having a major role in numerous medical disorders, including in the areas of oncology, neurology and cardiology. Aposense has developed a set of proprietary compounds with demonstrated ability to identify, bind and accumulate within apoptotic (dying) cells in-vivo. This technology addresses a huge market of unmet clinical need across a range of molecular imaging and therapeutic applications. [18]F-ML-10, Aposense's agent for the molecular imaging of apoptosis in vivo, using the PET modality, is currently in advanced clinical trials. |
|
Avraham Pharmaceuticals
Avraham Pharmaceuticals (Avraham) is a privately held, emerging pharmaceutical company developing novel products for treatment and/or prevention of neurodegenerative disorders. Founded in 2010, Avraham has raised $9 million for the development of its lead product candidate, ladostigil, through a Phase II proof-of-concept efficacy trial in patients with Alzheimer's disease in Europe.
Ladostigil is a novel cholinesterase and uniquely brain-selective monoamine oxidase inhibitor ("MAOI"), and neuroprotective agent designed to provide a comprehensive medical treatment for Alzheimer's disease and other neurodegenerative diseases. In Phase I and Phase IIa clinical trials, the drug has proven to be pharmacologically active, safe and well tolerated. Like other cholinesterase inhibitors currently on the market, ladostigil targets symptomatic relief in Alzheimer's patients. But unlike these drugs, ladostigil is the first multi-functional drug to reach clinical trials, acting via additional novel mechanisms of action and providing potential to improve the behavioral and psychological symptoms of dementia, such as depression and anxiety. Moreover, ladostigil has the potential to slow progression of clinical symptoms of Alzheimer's disease for sustained periods of time and to modify the pathology associated with the disease.
|
|
Biokine Therapeutics
Biokine Therapeutics Ltd. is an emerging biotechnology company developing novel drugs to treat Inflammation and Cancer. Biokine was established in late 2000 by scientists from the Weizmann Institute.
Biokine targets the Chemokine Receptor System. This is a key molecular mechanism that regulates the development of a group of pathologies including cancer, inflammatory disease and the emerging field of stem cell biology and tissue regeneration. The Company has developed a suite of unique approaches and is conducting preclinical and clinical research on several molecules discovered in-house.
Biokine’s leading molecule, BKT-140, a CXCR4 antagonist is currently testes in a phase I/II in cancer patients.
|
|
Thrombotech
Thrombotech is a biotechnology company developing a new type of thrombolitic modulator (THR-18). When combined with the only approved drug for stroke therapy, (tissue plasminogen activator [tPA]), THR-18 markedly improves efficacy and safety profile. As a result, Thrombotech's technology will extend the tPA therapeutic time window from three to nine hours, targeting ~85% of stroke embolic patients. In addition to its revolutionary impact on stroke severity and clinical outcome, THR-18 has a large market potential, reaching billions of dollars.
The Company has completed pre-clinical studies at different independent sites exploring THR-18’s unique mechanism of action. Thrombotech’s animal studies exhibited high efficacy and safety in two major clinical indications (stroke and traumatic brain injury). Furthermore, the Company has several patents on THR-18 derivatives with a similar spectrum of activities. Thrombotech completed a successful pre-IND meeting with the FDA and the first-in-man study is scheduled for 2010.
|
|
Braintact
Braintact Ltd. develops an innovative, proprietary blood glutamate scavenging platform, developed by Prof. Vivian Teichberg from the Weizmann Institute in Rehovot, Israel. This technology has potential to treat numerous acute and chronic neurodegenerative disorders, including traumatic brain injury (TBI), stroke, brain tumors (glioma), amyotrophic lateral sclerosis (ALS). At present no successful treatments are available for these severely disabling and often fatal diseases. Blood glutamate scavenging is a completely novel approach which represents a paradigm shift in the treatment of these diseases. |
|
ProtAb
ProtAb Ltd. is a biotechnology company focused on the development of novel therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. ProtAb was established in 2005 based on research from the laboratories of Professor Yaakov Naparstek, Chairman of Medicine at the Hadassah University Hospital.
ProtAb's first product - Proximab - is a promising monoclonal antibody with a unique mechanism of action currently in late-stage preclinical development for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases, specifically inflammatory bowel disease (IBD). Both of these are prevalent autoimmune diseases, with significant unmet clinical needs. The Company has already successfully completed the humanization of Proximab and established preclinical proof-of-concept for Proximab in experimental disease models of the two major clinical indications - RA and IBD. Late-stage development is ongoing, including GMP manufacturing and toxicology experiments, whereby initiation of a Phase I/IIA clinical trial in RA is scheduled
|
|
Campus Bio
Campus Bio focuses on the development of biopharmaceuticals and medical devices, licensed from Academic Institutes. Its vision is to advance compounds and technologies from early stages of discovery to clinical trials, regulatory approval and marketing.
The concept of Campus Bio is novel, combining the renowned expertise of CBI in drug development with the research excellence of the academia. This concept has created an exceptional structure of collaboration with the Weizmann institute through Yeda, in the early stage of proof of concept, through a mutual fund, as well as in advanced stages of the drug development.
|
|
CLS
Clal Life Sciences L.P. (CLS) is a Research and Development center established with a goal to provide optimal conditions for the growth of emerging life science companies. The CLS partnership is wholly owned by CBI. Established in 2000, CLS is Israel's only privately-held Research and Development center dedicated to biotechnology. The Center is located in Yavne, 30 kilometers south of Tel-Aviv.
The CLS Center offers its resident companies state-of-the-art research and development laboratories including a GMP manufacturing pilot plant, a central clean room facility and a modern animal house, built and run according to the highest GMP standards.
Four CBI portfolio companies have already set-up their operations in CLS: CureTech, MediWound, Polyheal, and Andromeda. |
|
|
